Namibia - English - Namibia Medicines Regulatory Council

fresenius kabi south africa (pty) limited - neostigmine methylsulphate - injection - each 1ml ampoule contains neostigmine methylsulphate 0.5mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - neostigmine methylsulphate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - neostigmine methylsulphate -

Zimbabwe - English - Medicines Control Authority

fresenius kabi manufacturing s.a pvt ltd, - neostigmine methylsulphate - injectable; injection - 0.5mg/ml

Zimbabwe - English - Medicines Control Authority

fresenius kabi manufacturing s.a pvt ltd, - neostigmine methylsulphate - injectable; injection - 2.5mg/ml

Kenya - English - Pharmacy and Poisons Board

fresenius kabi manufacturing sa (pty) limited 6 gibaud road korsten port elizabeth 6020 south - neostigmine methylsulphate - injection - 2.5 mg/1 ml - parasympathomimetics: anticholinesterases

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 1 mg in 1 ml - neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (nmba) after surgery.  neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).  - peritonitis or mechanical obstruction of the urinary or intestinal tracts. pregnancy risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.  it is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited.  all pregnancies, regardless of drug e

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - neostigmine methylsulfate (unii: 98imh7m386) (neostigmine - unii:3982twq96g) - neostigmine methylsulfate 0.5 mg in 1 ml - neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (nmba) after surgery.  neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis).  - peritonitis or mechanical obstruction of the urinary or intestinal tracts. risk summary there are no adequate or well-controlled studies of neostigmine methylsulfate injection in pregnant women.  it is not known whether neostigmine methylsulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  the incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited.  all pregnancies, regardless of drug exposure, h

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - neostigmine metilsulfate 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: neostigmine metilsulfate 0.5 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - neostigmine metilsulfate 2.5 mg/ml - solution for injection - 2.5 mg/ml - active: neostigmine metilsulfate 2.5 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - · reversal of the effects of nondepolarising neuromuscular blocking agents (e.g. tubocurarine, pancuronium etc.).